Mutant KRAS could up-regulate immunosuppressive cells in tumor such as myeloid-derived suppressor cells (MDSCs), CD4+FoxP3+ T regulatory cells, and CD19+IL10+ B regulatory cells. Here, KRAS is linked to neoplasm.